PURPOSE: Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four human osteosarcoma cell lines. METHOD: Cell growth, secretion of soluble Fas, expression of cell-surface Fas, and sensitivity to Fas-mediated cell death were examined using cell proliferation assay, flow cytometry, enzyme-linked immunosorbent assay, and agonistic anti-Fas antibody, respectively. RESULTS: VPA suppressed the growth of all the four osteosarcoma cell lines and the secretion of soluble Fas from these cells. VPA showed no or slight suppressive effect on the expression of cell-surface Fas in the four osteosarcoma cell lines, but increased the sensitivity of three of four osteosarcoma cell lines to Fas-mediated cell death. CONCLUSION: VPA enhances the susceptibility of human osteosarcoma cells to Fas-ligand-induced cell death by decreasing the secretion of soluble Fas and increasing the sensitivity to Fas-mediated cell death.
PURPOSE: Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four humanosteosarcoma cell lines. METHOD: Cell growth, secretion of soluble Fas, expression of cell-surface Fas, and sensitivity to Fas-mediated cell death were examined using cell proliferation assay, flow cytometry, enzyme-linked immunosorbent assay, and agonistic anti-Fas antibody, respectively. RESULTS:VPA suppressed the growth of all the four osteosarcoma cell lines and the secretion of soluble Fas from these cells. VPA showed no or slight suppressive effect on the expression of cell-surface Fas in the four osteosarcoma cell lines, but increased the sensitivity of three of four osteosarcoma cell lines to Fas-mediated cell death. CONCLUSION:VPA enhances the susceptibility of humanosteosarcoma cells to Fas-ligand-induced cell death by decreasing the secretion of soluble Fas and increasing the sensitivity to Fas-mediated cell death.
Authors: Qinghua Xia; Jennifer Sung; Wasim Chowdhury; Chien-Lun Chen; Naseruddin Höti; Shabana Shabbeer; Michael Carducci; Ronald Rodriguez Journal: Cancer Res Date: 2006-07-15 Impact factor: 12.701
Authors: F Leithäuser; J Dhein; G Mechtersheimer; K Koretz; S Brüderlein; C Henne; A Schmidt; K M Debatin; P H Krammer; P Möller Journal: Lab Invest Date: 1993-10 Impact factor: 5.662
Authors: S Ueshima; T Aiba; T Makita; S Nishihara; Y Kitamura; Y Kurosaki; H Kawasaki; T Sendo; Y Ohtsuka; Y Gomita Journal: J Clin Pharm Ther Date: 2008-02 Impact factor: 2.512
Authors: Luke A Wittenburg; Liam Bisson; Barbara J Rose; Christopher Korch; Douglas H Thamm Journal: Cancer Chemother Pharmacol Date: 2010-03-20 Impact factor: 3.333